Khullar Vik, Hill Simon, Laval Karl-Ulrich, Schiøtz Hjalmar A, Jonas Udo, Versi Eboo
Department of Obstetrics and Gynaecology, Imperial College School of Medicine, London, United Kingdom.
Urology. 2004 Aug;64(2):269-74; discussion 274-5. doi: 10.1016/j.urology.2004.02.029.
To examine the efficacy and tolerability of antimuscarinic therapy in women with urge-predominant mixed incontinence.
This was a double-blind, randomized, placebo-controlled trial comprising 854 women with urge-predominant mixed incontinence, including urge incontinence (five or more episodes per week), urinary frequency (eight or more micturitions on average in 24 hours), and urgency in combination with stress incontinence. Women received 8 weeks of treatment with tolterodine tartrate extended-release (ER) 4 mg or placebo once daily. The outcome measures included urge incontinence episodes per week, stress incontinence episodes per week, micturition frequency per 24 hours, urgency episodes per 24 hours, volume voided per micturition, patient perception of bladder condition, and assessment of treatment benefit.
After 8 weeks, tolterodine ER produced a statistically significant decrease in the weekly urge incontinence episodes compared with placebo (-12.3 versus -8.0; P <0.0001). Other micturition variables improved significantly more with tolterodine ER. No difference was found between treatment groups regarding the change in the number of stress incontinence episodes. A significantly greater proportion of patients receiving tolterodine ER than those receiving placebo reported improvement in bladder condition (61% versus 46%; P <0.001) and treatment benefit (76% versus 55%; P <0.001). After 8 weeks, the tolterodine ER group had experienced statistically significant improvements compared with the placebo group in 9 of 10 quality-of-life domains. The frequency of adverse events was similar between treatment groups.
Tolterodine ER is an effective treatment of urge urinary incontinence, frequency, and urgency in women with concomitant stress urinary incontinence. The efficacy of tolterodine ER in reducing urge incontinence episodes was unaffected by the presence of stress incontinence. The results of this study support the first-line use of antimuscarinic therapy to treat the urge incontinence component of urge-predominant mixed incontinence.
探讨抗毒蕈碱疗法对以尿急为主的混合性尿失禁女性患者的疗效和耐受性。
这是一项双盲、随机、安慰剂对照试验,纳入854例以尿急为主的混合性尿失禁女性患者,包括急迫性尿失禁(每周发作5次或更多次)、尿频(24小时平均排尿8次或更多次)以及尿急合并压力性尿失禁。患者接受为期8周的治疗,每日一次口服4毫克酒石酸托特罗定缓释片或安慰剂。观察指标包括每周急迫性尿失禁发作次数、每周压力性尿失禁发作次数、24小时排尿频率、24小时尿急发作次数、每次排尿量、患者对膀胱状况的感知以及治疗获益评估。
8周后,与安慰剂相比,酒石酸托特罗定缓释片使每周急迫性尿失禁发作次数有统计学意义的显著减少(-12.3对-8.0;P<0.0001)。其他排尿变量在酒石酸托特罗定缓释片治疗组改善更为显著。治疗组之间压力性尿失禁发作次数的变化无差异。与接受安慰剂的患者相比,接受酒石酸托特罗定缓释片的患者中报告膀胱状况改善(61%对46%;P<0.001)和治疗获益(76%对55%;P<0.001)者比例显著更高。8周后,与安慰剂组相比,酒石酸托特罗定缓释片组在10个生活质量领域中的9个领域有统计学意义的显著改善。治疗组之间不良事件发生率相似。
酒石酸托特罗定缓释片是治疗伴有压力性尿失禁的女性患者急迫性尿失禁、尿频和尿急的有效药物。酒石酸托特罗定缓释片减少急迫性尿失禁发作次数的疗效不受压力性尿失禁存在的影响。本研究结果支持抗毒蕈碱疗法一线用于治疗以尿急为主的混合性尿失禁中的急迫性尿失禁成分。